Insider Selling: Teva Pharmaceutical Industries (NYSE:TEVA) Insider Sells 1,127 Shares of Stock

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) insider Brian Savage sold 1,127 shares of the stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total value of $35,692.09. Following the completion of the sale, the insider directly owned 10,914 shares of the company’s stock, valued at approximately $345,646.38. The trade was a 9.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA traded up $0.39 during mid-day trading on Monday, hitting $31.44. The stock had a trading volume of 11,093,304 shares, compared to its average volume of 9,695,220. The company’s 50 day simple moving average is $33.01 and its 200 day simple moving average is $26.32. The stock has a market cap of $36.15 billion, a price-to-earnings ratio of 26.20, a PEG ratio of 10.39 and a beta of 0.72. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. Teva Pharmaceutical Industries Ltd. has a twelve month low of $12.47 and a twelve month high of $37.35.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 28th. The company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a return on equity of 46.28% and a net margin of 8.16%.The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.36 billion. During the same period in the previous year, the company posted $0.71 EPS. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Institutional Trading of Teva Pharmaceutical Industries

Large investors have recently made changes to their positions in the company. Aster Capital Management DIFC Ltd bought a new stake in Teva Pharmaceutical Industries during the fourth quarter worth $25,000. Allworth Financial LP lifted its position in shares of Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock worth $29,000 after buying an additional 329 shares during the last quarter. Grove Bank & Trust boosted its stake in Teva Pharmaceutical Industries by 300.0% in the fourth quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock valued at $31,000 after buying an additional 750 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Teva Pharmaceutical Industries by 51.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock valued at $32,000 after acquiring an additional 345 shares during the last quarter. Finally, Advisors Asset Management Inc. acquired a new position in Teva Pharmaceutical Industries during the second quarter worth about $41,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Teva Pharmaceutical Industries News Summary

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Recent fundamentals and guidance support the stock’s strength — Teva beat Q4 EPS and revenue in its Jan 28 report, reported improving margins and set FY2026 EPS guidance of 2.57–2.77, which gives investors clearer earnings visibility and helps justify the rally.
• Neutral Sentiment: Management presented at the Leerink Global Healthcare Conference; the transcript provides investor-facing commentary on strategy, pipeline and commercial performance but contains no market-moving surprise in the headlines. Teva Presents at Leerink Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Heavy insider selling reported on March 5 by multiple senior executives (CEO and several EVPs). Notable filings show CEO Richard D. Francis sold 20,025 shares (~$31.67 avg), and other insiders (Placid Jover, Richard Daniell, Eric A. Hughes, Christine Fox, Brian Savage) also trimmed positions — in some cases materially (Placid Jover’s position fell ~67.6%). Large, clustered insider sales can weigh on sentiment even if they are for diversification or tax reasons. SEC filing for the CEO sale is available here: CEO Filing. The sales were also summarized by the press: Insider Selling: CEO Sells

Wall Street Analysts Forecast Growth

TEVA has been the topic of a number of recent research reports. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. The Goldman Sachs Group upped their price target on shares of Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, February 9th. Truist Financial boosted their price objective on shares of Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Finally, Wall Street Zen upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $37.67.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.